| Name | Belvarafenib |
| Description | Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM. |
| In vitro | Belvarafenib (HM95573) inhibited B-RAF, B-RAFv600E and C-RAF with IC50 values of 56, 7 and 5 nM, respectively.[1] |
| In vivo | METHODS: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023.EAP patients were treated with 450 mg of Belvarafenib (HM95573) twice daily.
RESULTS Six patients with NRAS or RAF alterations were treated with Belvarafenib (HM95573), and 50% of the patients had control of their disease, including two patients with significant outcomes. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (52.2 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.09 mM), Sonication is recommended.
|
| Keywords | RG-6185 | RG6185 | RG 6185 | Raf kinases | Raf | Inhibitor | inhibit | HM-95573 | HM95573 | HM 95573 | GDC-5573 | GDC5573 | GDC 5573 | Belvarafenib |
| Inhibitors Related | Regorafenib monohydrate | Exarafenib | Doramapimod | Vemurafenib | Sulindac sulfide | Sorafenib | Regorafenib | Dabrafenib | Dabrafenib Mesylate | LY3009120 | GW 441756 | RMC-7977 |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |